NHS FORTH VALLEY Multiple Sclerosis Service Management of MS Relapses



Similar documents
Intravenous Methyl Prednisolone in Multiple Sclerosis

Patient Sticker Multiple Sclerosis Ambulatory Emergency Care Pathway

RELAPSE MANAGEMENT. Pauline Shaw MS Nurse Specialist 25 th June 2010

Understanding Relapse in Multiple Sclerosis. A guide for people with MS and their families

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients

Gilenya. Exceptional healthcare, personally delivered

Managing the Symptoms of Multiple Sclerosis. Yolanda Harris, MSN, CRNP-AC CPODD Nurse Practitioner

Teriflunomide (Aubagio) 14mg once daily tablet

Medical Insurance Long Term (chronic) Conditions Explained

Steroids. What are steroids?

REHABILITATION MEDICINE by PROFESSOR ANTHONY WARD

Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU

National Hospital for Neurology and Neurosurgery. Managing Spasticity. Spasticity Service

COPD - Education for Patients and Carers Integrated Care Pathway

Clinical Commissioning Policy: Disease Modifying Therapies For patients With Multiple Sclerosis (MS) December Reference : NHSCB/D4/c/1

Shared Care Guideline-Use of Donepezil, Galantamine, Rivastigmine and Memantine in Dementia

Treatment of diseases affecting the kidney using steroids

NHS BOURNEMOUTH AND POOLE AND NHS DORSET

Community health care services Alternatives to acute admission & Facilitated discharge options. Directory

Rivaroxaban: Prescribing Guidance for the treatment of provoked venous thromboembolism (VTE)

Lymphoma and palliative care services

Adult Neuromuscular pathway (Dec 2014) (18 years onwards)

PROCEDURE FOR BLOOD GLUCOSE MONITORING

REHABILITATION. begins right here

About MS. An introduction to. An introduction to multiple sclerosis for people who have recently been diagnosed. What is MS? Is it common?

Optic Neuritis. The optic nerve fibers are coated with myelin to help them conduct the electrical signals back to your brain.

Treating symptoms. An introduction to. Everyone diagnosed with MS can get treatment for their symptoms. The symptoms of MS. Who can get treatment?

Dizziness and balance problems

Neurorehabilitation Strategy Briefing Document and Position Paper

BE SURE. BE SAFE. VACCINATE.

GP Round Up Introduction by Alistair Flowerdew Medical Director

Macmillan Oldham Community Specialist Palliative Care Team. An information guide

How To Fill Out A Health Declaration

A Definition of Multiple Sclerosis

Low Back Pain Protocols

CLINICAL GUIDELINE FOR MANAGEMENT OF NEUTROPENIC SEPSIS IN CANCER PATIENTS 1. Aim/Purpose of this Guideline

Cheshire and Merseyside Rehabilitation Network Referral Criteria

Discharge Information Information for patients This leaflet is intended to help you, your carer, relatives and friends understand and prepare for

Mellen Center for Multiple Sclerosis

Gwen Griffith Clinical Nurse Specialist Bolton NHS foundation Trust

Treatment for Stress Incontinence Patient Decision Aid

2. Characteristics of staff Qualifications required. Additional requirements. Continued education & training requirements

POAC CLINICAL GUIDELINE

Rehabilitation Medicine Service for Adults with Physical Disabilities

Relapsing-remitting multiple sclerosis Ambulatory with or without aid

Rehabilitation and the role of carers

Review Date: March Issue Status: Approved Issue No: 2 Issue Date: March 2010

What is Multiple Sclerosis? Gener al information

Intravenous Immunoglobulin in Neurological disorders

Professional resources First edition June Translating the NICE and NSF guidance into practice A guide for occupational therapists

Inhaled and Oral Corticosteroids

Community Rehabilitation Beds. Questions and Answers

6/3/2011. High Prevalence and Incidence. Low back pain is 5 th most common reason for all physician office visits in the U.S.

Guide to Claims against General Practitioners (GPs)

Problems in Early Pregnancy

Contents Page. 1. What is IV DHE? Medication Licence How can a course of IV DHE help? What are the side effects of IV DHE?

Spine University s Guide to Vertebral Osteonecrosis (Kummel's Disease)

The Physiotherapy Pilot. 1.1 Purpose of the pilot

Medication and Devices for Chronic Obstructive Pulmonary Disease (COPD)

Service Specification Template Department of Health, updated June 2015

Connection with other policy areas and (How does it fit/support wider early years work and partnerships)

Your Huntercombe How do I make a referral?

NICE Pathways bring together all NICE guidance, quality standards and other NICE information on a specific topic.

Cardiac Catheter Lab Information for patients having a Coronary Angiogram

Electroconvulsive Therapy - ECT

Prescribing Framework for Donepezil in the Treatment and Management of Dementia

Adjunctive psychosocial intervention. Conditions requiring dose reduction. Immediate, peak plasma concentration is reached within 1 hour.

Essential Shared Care Agreement Drugs for Dementia

MS Treatments Aubagio TM

Information on termination of pregnancy (abortion) A series of information leaflets on termination of pregnancy services in Greater Glasgow & Clyde

IMPROVING ADULT PHYSICAL REHABILITATION SERVICES

Spine Care Centre (SCC) protocols for Multiple Sclerosis Update 1 August 2015

KIH Cardiac Rehabilitation Program

CLINICAL PRACTICE GUIDELINES FOR MANAGEMENT OF LOW BACK PAIN

Multiple sclerosis disease-modifying drugs second line treatments

Rivaroxaban to prevent blood clots for patients who have a lower limb plaster cast. Information for patients Pharmacy

Hospital ID: SS ID: NHS No: NI No: Surname: Forename: D.O.B:

Client Summary Palliative Care

How To Cover Occupational Therapy

SOUTH TAMPA MULTIPLE SCLEROSIS CENTER

Dabigatran: Amber Drug Guidance for the prevention of stroke and systemic embolism in patients with non-valvular AF

Transcription:

NHS FORTH VALLEY Multiple Sclerosis Service Management of MS Relapses Approved 22/06/2010 Version Version 2 Date of First Issue 2002 Review Date 10/05/2016 Date of Issue 01/02/2010 EQIA Yes 22.06.10 Author / Contact Dr C, Consultant Neurologist Group / Committee Final Approval Neurology Managed Care Network Version: 2 1 st February 2010 Page 1 of 9

NHS Forth Valley Consultation and Change Record Contributing Authors: Consultation Process: Distribution: Dr. M. A. MacLeod, Consultant Neurologist Dr. C., Consultant Neurologist Dr. M. MacLeod, Reader in Clinical Neurosciences & Honorary Consultant Neurologist Dr. S. McCallan, Associate Specialist in Neurological Rehabilitation Dr. S. Cumming, General Practitioner & Clinical Lead Community Health Partnership Stirling Hazel Gaylor, Multiple Sclerosis Specialist Nurse MS Service Information Provision NHS Forth Valley Intranet Service Information Directory Change Record Date Author Change Version Dr. McLeod Author 2002 Dr. C. Change to oral dosing regime in line with best practice and NICE guidelines for MS No. 18 2007 Dr. C. Reviewed algorithm and Appendix1 added 2010 10.05.11 Dr C. Reviewed with no changes made. Next review date 10.05.12 2 04.07.2012 Dr C 19.03.2014 Dr C Reviewed with no changes made. 2 Reviewed with no changes made 2 Version: 2 1 st February 2010 Page 2 of 9

FORTH VALLEY MULTIPLE SCLEROSIS SERVICE MANAGEMENT OF MS RELAPSES About 15% of MS patients have relapsing remitting MS and suffer from regular relapses. Some patients with progressive MS can also have relapses. A relapse is defined as an acute deterioration in neurological function lasting 24 hours or more. Many MS relapses are mild and non-disabling such as an episode of upper limb numbness. Others are severely disabling and can result in an individual being bed bound, or unable to self-care or work. WHAT CAUSES MS RELAPSES About 25% of MS relapses are related to an underlying infection such as an upper respiratory tract or urinary tract infection. Many occur for no apparent reason. If an MS patient has a relapse then it is important to look for the underlying infection. Often appropriate treatment of this will speed up recovery from the infection and avoid the need for steroids. It is important to distinguish an acute relapse from a temporary deterioration due to tiredness or stress, or from progression of the disease. Recent evidence has shown that there is no definite association between vaccination and an MS relapse. In addition it has been shown that relapses are less likely to occur during pregnancy but are slightly more common in the first few weeks post-partum. Version: 2 1 st February 2010 Page 3 of 9

STEROIDS IN MS RELAPSES Steroids have been shown to speed up the recovery of an MS relapse. However, they have no influence on the eventual outcome and resultant disability. (Some papers a few years ago raised the possibility that steroids in optic neuritis may influence the development of MS but this has been questioned). Currently there is no evidence that steroids affect the long-term course of disease in MS Steroids should only be used if the relapse is truly disabling and not simply progression of disease. In general steroids are not used in a purely sensory upset and are reserved for more severe episodes. This is partly because of the risk of side effects such as avascular necrosis of the hip and partly because with more frequent use of steroids the benefits appear to wear off. (This may simply reflect worsening disease). Steroids SHOULD NOT be used if there is evidence of underlying infection. All patients should be questioned about symptoms of a chest or urinary or other infection. Venous blood should be taken for FBC, U&E s, CRP and an MSSU should be processed. Treatment of the infection might avoid the need for steroids. WHICH ROUTE Intravenous A short course e.g. intravenous methyl prednisolone, 1gm daily for three days, can be given. We do not recommend a tapering dose of oral steroids. Oral Steroids Alternatively, oral prednisolone can be given, e.g. High dose methylprednisolone, 500mg-2g daily for between 3 and 5days. It is recommended to prescribe an oral proton pump inhibitor for approximately one month from treatment. There is no evidence that one route is better than the other and we often let the patient choose. Continued courses of steroids, or a second course if the first didn t work, are not recommended. Version: 2 1 st February 2010 Page 4 of 9

HOW OFTEN We do not recommend more than 2 courses of steroids a year. MS patients are often immobile and already at increased risk of osteoporosis. This can be made worse by steroids. In addition there is a risk of avascular femoral head necrosis and cataract with increasing use of steroids. STEROID DEPENDENCE Some patients with secondary progressive MS may become steroid dependent. Steroids can often give a sense of well being without influencing disability and patients may request steroids when feeling low. They are contraindicated in this situation. SIDE EFFECTS Other than those stated, in the short term patients can be at risk of steroid induced hyperglycaemia, hypertension, psychosis, reactivation of underlying infection and peptic ulceration. FOLLOW UP Patients may be left with new disability following a relapse, which may or may not be helped by steroids. Consideration should be given to referral for physiotherapy, occupational therapy or speech and language therapy. In addition symptomatic management of pain, spasticity etc may be appropriate in the short or long term. Version: 2 1 st February 2010 Page 5 of 9

TREATMENT OF MS RELAPSES Before treating an MS patient for a relapse have you considered: 1. Is this a disabling true relapse or is this progression of disease or a temporary deterioration related to low mood, fatigue, stress or other circumstances 2. Is there an underlying infection? Check infection screen and ask about symptoms of a chest infection, UTI etc. NB: PATIENTS WITH MS CAN OFTEN HAVE A SUBCLINICAL UTI OR MAY FIND THE SYMPTOMS OF A UTI DIFFICULT TO DIFFERENTIATE FROM SYMPTOMS OF MS. VENOUS BLOOD SHOULD BE TAKEN FOR FBC, U&E s, CRP AND AN MSSU SHOULD BE PROCESSED 3. Have steroids been used recently or several times in the past year? As a rule of thumb, a maximum 2 courses of steroids should be used a year 4. Have you documented clinical history and findings? This may be important if the patient is to be considered for disease modifying treatment. 5. Does the patient require follow up in the MS clinic? Do they need referral for rehabilitation in the meantime? Can they cope at home whilst suffering this relapse? Do they require symptomatic treatment during the relapse? 6. If the patient requires admission to the wards or intravenous methyl prednisolone as a day case and they have a. No evidence of infection b. A clearly disabling relapse c. Not had more than 2 courses this year d. Are suitable for day case IV Methyl prednisolone If the patient does not fulfill the above criteria, and does not require admission, please contact the MS team and we will fit them into a clinic slot ASAP. There are weekly MS clinics held with a slot kept free for this situation. IF IN DOUBT, WE ARE HAPPY TO ASSESS THE PATIENT IN THE MS CLINIC FIRST Neurology Department Falkirk & District Royal Infirmary Majors Loan Falkirk FK1 5QE 01324 624000 Ext 8631 Dr. C. Consultant Neurologist Hazel Gaylor MS Nurse Specialist Madeleine Steele MS Support Nurse Jody McCormack MS Secretary Version: 2 1 st February 2010 Page 6 of 9

REPORTING / RECORDING OF SYMPTOMS BY PATIENT / PARTNER / FAMILY / CARERS / G.P. TO M.S. NURSE / CONSULTANT/ GP NEW SYMPTOMS OR ACUTE WORSENING OF EXISTING SYMPTOMS OR PROBLEMS YES YES NO NURSING / GP / MEDICAL ASSESSMENT HISTORY OF RECENT INFECTION OR ILLNESS NO NO AWAIT EXPECTED TIME FOR TREATMENT TO COMPLETE OR ILLNESS TO RESOLVE INFECTION SCREEN FOR NEW OR HIDDEN PROBLEMS (APPENDIX I) -VE RESOLVED? +VE YES TREAT INFECTION and/or PRECIPITATING FACTORS OUTRULE OTHER CAUSES e.g. migraine, natural visual change, sciatica, nerve entrapment, physical injury, inner ear problem SYMPTOMS MOST LIKELY TO BE MS RELATED YES NO GIVE STEROID TREATMENT (Appendix 3) STEROIDS CONTRA-INDICATED (Appendix 2) TREAT CONSERVATIVELY REVIEW / REASSESS: REFER TO OTHER SPECIALIST MEDICAL / NURSING / MDCT / G.P. Version: 2 1 st February 2010 Page 7 of 9

APPENDICES APPENDIX 1 APPENDIX 2 APPENDIX 3 INFECTION SCREEN: CONTRA-INDICATIONS STEROID PROTOCOLS TEMP > 37.5 deg C HISTORY OF PSYCHOSIS ORAL METHYL PREDNISOLONE PER LOCAL MS RELAPSE PROTOCOL CRP >10 SEVERE DEPRESSION WCC >10 ACUTE OSTEOPOROSIS IV METHYL PREDNISOLONE : +VE URINALYSIS UNSTABLE IDDM AS PER LOCAL MS RELAPSE PROTOCOL SUSPECT SPUTUM ACTIVE GASTRIC ULCERATION AT DAY MEDICINE FDRI INFECTED WOUND RECTAL BLEEDING ORAL / VAGINAL THRUSH EXPLAIN RATIONALE AND SIDE EFFECTS DIARRHOEA GIVE INFORMATION LEAFLETS THROAT INFECTION GAIN INFORMED CONSENT GIVE STEROID CARD ACTION SEND SPECIMEN TO LAB: SPUTUM / M.S.S.U. / C.S.U./ SWABS / BLOOD FBC, U&E s, CRP AWAIT RESULT Version: 2 1 st February 2010 Page 8 of 9

Publications in Alternative Formats NHS Forth Valley is happy to consider requests for publications in other language or formats such as large print. To request another language for a patient, please contact 01786 434784. For other formats contact 01324 590886, text 07990 690605, fax 01324 590867 or e-mail - fv-uhb.nhsfv-alternativeformats@nhs.net Version: 2 1 st February 2010 Page 9 of 9